M&A Deal Summary

SK Capital Partners Acquires Apotex

On September 28, 2022, private equity firm SK Capital Partners acquired life science company Apotex

Acquisition Highlights
  • This is SK Capital Partners’ 5th transaction in the Life Science sector.
  • This is SK Capital Partners’ 3rd transaction in Canada.
  • This is SK Capital Partners’ 1st transaction in Ontario.

M&A Deal Summary
Date 2022-09-28
Target Apotex
Sector Life Science
Buyer(s) SK Capital Partners
Deal Type Buyout (LBO, MBO, MBI)
Advisor(s) Rothschild Global Advisory (Financial)
Davies Ward Phillips & Vineberg LLP (Legal)

Target

Apotex

Toronto, Ontario, Canada
website
Apotex is an independent pharmaceutical company committed to R&D, manufacturing, and distributing a broad range of high-quality, affordable medicines to patients, healthcare providers, payers, and governments worldwide. Apotex was founded in 1974 and is based in Toronto, Ontario.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

SK Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor

website

Category Private Equity Firm
Founded 2007
PE ASSETS 4.9B USD
Size Large
Type Sector Agnostic
DESCRIPTION

SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.

DEAL STATS #
Overall 36 of 39
Sector (Life Science) 5 of 5
Type (Buyout (LBO, MBO, MBI)) 6 of 6
State (Ontario) 1 of 1
Country (Canada) 3 of 3
Year (2022) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-01 Luxium Solutions

Hiram, Ohio, United States

Luxium Solutions is a provider of single scintillation crystals for radiation detection applications, as well as sapphire and garnet substrates for photonics and power electronics applications. Luxium Solutions was founded in 1969 and is based in Hiram, Ohio.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-16 TPC Group

Houston, Texas, United States

TPC Group is a producer of value-added products derived from niche petrochemical raw materials such as C4 hydrocarbons. The Company processes C4 hydrocarbons into butadiene, butene-1, isobutylene and differentiated isobutylene derivatives for use in performance and specialty products in the synthetic rubber, fuels, lubricants, plastics and nylon industries. It also produces a variety of C3 derivatives for use in plasticizers, surfactants and antioxidants. TPC Group was founded in 1943 and is based in Houston, Texas.

Sell -
Mergr

Product

Company

Legal